Hvivo secures £2.5 million contract for Covid-19 characterisation study

Hvivo, a pharmaceutical services company listed on the Dublin and London stock exchanges, has secured a £2.5 million (€2.9m) contract with a mid-sized pharmaceutical company to start a Covid-19 characterisation study. In 2023, Hvivo successfully completed the manufacture of its Omicron BA.5 challenge agent. The upcoming study aims to determine a dose of this agent that induces a safe, measurable, and reproducible disease in healthy volunteers, achieving high infection rates necessary for testing the efficacy of antivirals and vaccines in the future.

Recruitment for the study will target healthy volunteers aged 18 to 30 who have received a full course of a licensed Covid-19 vaccine. Characterisation studies provide biopharma clients with precise, actionable insights into specific pathogens, supporting and refining vaccine or antiviral development. They also generate crucial data needed for designing subsequent antiviral or vaccine efficacy testing studies.

The study is set to begin in the final quarter of this year, with most of the revenue to be recognised in 2025. Subject to successful completion and regulatory approvals, Hvivo anticipates conducting multiple Omicron human challenge trials to test medical product efficacy from mid-2025.

Yamin “Mo” Khan, Hvivo’s chief executive, highlighted the company’s goal to diversify its challenge trial offerings. Establishing a Covid challenge model is seen as a critical step in accessing a new and expanding market, particularly for mucosal and multi-valent Covid vaccine development.

Dr Andrew Catchpole, chief scientific officer of Hvivo, expressed excitement about characterising the Omicron challenge agent, facilitated by the company’s new CL3 facilities in Canary Wharf. He emphasised Hvivo’s leading expertise in characterising Sars-CoV-2 challenge agents, noting their successful conduct of the world’s first Covid-19 characterisation study. The client’s funding for this study underscores the strong interest and growing pipeline in this area, driven by the ongoing global health threat posed by Covid-19, especially the Omicron strain, and the need for improved vaccines and treatments.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Clinical trial eligibility: Pre-screening and Screening

    In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

    hVIVO plc

    Connecting Airway Epithelial Cell Models with Human Challenge Studies

    Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

    hVIVO plc

    Esmée shares her FluCamp clinical trial volunteer experience

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Overcoming challenges in high-growth regulated industries

    The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

    hVIVO plc

    Take a 360° interactive tour of a FluCamp Volunteer Room

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Clinical trial approval process in the UK

    The process of obtaining approval for clinical trials is comprehensive, as it involves multiple regulatory bodies that ensure the safety and efficacy of the medical interventions being tested. Researchers begin by meticulously planning the trial, outlining

    hVIVO plc

    hVIVO reports positive results from RSV antiviral human challenge trial

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the announcement by Enanta Pharmaceuticals, reporting positive topline results from

    hVIVO plc

    The importance of Clinical Trial Monitoring

    Monitoring is essential from the moment a clinical trial is planned until it concludes. This ensures that the study remains unbiased, patient safety is prioritised, and accurate results are achieved. The process of clinical trial monitoring

    hVIVO plc

    The future of vaccine development through human challenge trials

    Testing new treatments and vaccines often requires years, if not decades, to gather sufficient data. In response, scientists are turning to a more direct approach that involves deliberately infecting volunteers with potentially deadly pathogens. A notable

    hVIVO plc

    The impact of Clinical Trial results on medical advancements

    Clinical trials play a pivotal role in advancing the medical industry by allowing new treatments and interventions to be rigorously tested for both effectiveness and safety. Understanding how clinical trial data is used is essential to

    hVIVO plc

    Hvivo reports significant growth in earnings and revenue

    Hvivo, previously known as Open Orphan, saw a significant increase in earnings during the first six months of the year, marking a 67.6% rise. Earnings before interest, taxes, depreciation, and amortisation reached £8.7 million (€10.32 million),

    hVIVO plc

    hVIVO reports strong first half, delivering record revenues and margins

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its unaudited interim results for the six-month period ended 30 June 2024.

    hVIVO plc

    hVIVO expands to cutting-edge facility in Canary Wharf

    hVIVO plc, a specialist contract research organisation (CRO), is experiencing rapid growth, establishing itself as the global leader in testing vaccines and therapeutics for infectious and respiratory diseases. By conducting human challenge clinical trials, the company